Exelixis Inc (EXEL) Actualités

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter...

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025

– In a subgroup analysis of patients without liver metastases, adding atezolizumab to zanzalintinib led to enhanced progression-free survival and...

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

– Cabozantinib reduced the risk of disease progression or death by 50 percent compared with placebo in patients with advanced gastrointestinal...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities